# Eikon Therapeutics

Source: https://onco.cc/companies/eikon-therapeutics/  
OnCo record `eikon-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eikon Therapeutics is a United States-based biotechnology company running 6 late-stage cancer trials of EIK1001, EIK1004-001 (IMP1707-001) and IMP1734 in melanoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer.

## Summary

Eikon Therapeutics, based in Millbrae, California, the United States, is a biotechnology company. A drug discovery company that also has offices in New York and Jersey City and lists clinical-stage oncology, immunology and neuroscience programmes on its pipeline page, including TLR7/8, PARP1, PARP1-CNS penetrant, AR, VCP and AR-v7 targeted programmes. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing EIK1001, EIK1004-001 (IMP1707-001), IMP1734 and EIK1005 in melanoma, non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, colorectal cancer and endometrial cancer. The largest, NCT07365319 (A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer), plans to enrol 750 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor
- HQ: Millbrae, California
- Type: biotech
- Website: https://www.eikontx.com

## Sources

- Official website: https://www.eikontx.com
- ClinicalTrials.gov: trials led by Eikon Therapeutics: https://clinicaltrials.gov/search?lead=Eikon%20Therapeutics

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [EIK1001](https://onco.cc/drugs/eik1001/), [EIK1005](https://onco.cc/drugs/eik1005/), [IMP1734](https://onco.cc/drugs/imp1734/)
- companies: [Lux Capital](https://onco.cc/companies/lux-capital/)
- trials: [A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06253130/), [A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC](https://onco.cc/trials/nct06246110/), [A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07365319/), [A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.](https://onco.cc/trials/nct06907043/), [EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic](https://onco.cc/trials/nct07262619/), [Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma](https://onco.cc/trials/nct06697301/)

---
JSON: https://onco.cc/api/v1/entities/eikon-therapeutics.json